Congestive heart failure during imatinib mesylate treatment

Turrisi, Gina; Montagnani, Francesca; Grotti, Simone; Marinozzi, Claudio; Bolognese, Leonardo; Fiorentini, Giammaria

doi:10.1016/j.ijcard.2009.07.006

Cited by 26 publications

(18 citation statements)

References 13 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…22 Previous reports described cardiotoxicity resulting from therapy with sunitinib, 23,24 sorafinib, 24 and imatinib mesylate. 25 Although the clinical occurrence and/or significance of the latter are being disputed, [26][27][28][29][30][31][32][33] reengineering efforts have been undertaken to alleviate the problem. 34 More recently, QTc prolongation and myocardial infarction related to dasatinib therapy have been reported.…”

Section: Discussionmentioning

confidence: 99%

Clinical cardiac safety profile of nilotinib

Kim¹,

Coutre²,

Schwarz³

et al. 2012

Haematologica

View full text Add to dashboard Cite

BackgroundNilotinib is a second-generation tyrosine kinase inhibitor with significant efficacy as first-or second-line treatment in patients with chronic myeloid leukemia. Despite preclinical evidence indicating a risk of prolongation of the QT interval, which was confirmed in clinical trials, detailed information on nilotinib's cardiac safety profile is lacking. Design and MethodsHere, we retrospectively assessed cardiovascular risk factors in 81 patients who were being or had previously been treated with nilotinib therapy and evaluated cardiovascular parameters by longitudinal monitoring of the QT interval and left ventricular ejection fraction. Detailed information on the occurrence and management of defined cardiac adverse events was extracted. ResultsThe median duration of nilotinib therapy was 26 months (range, 1-72). The median QT interval at baseline was 413 msec (range, 368-499 msec). During follow-up, the median QT was not significantly different from the baseline value at any time-point. Sixteen of 81 patients (20%) had new electrocardiographic changes. Cardiac function, as assessed by measurement of left ventricular ejection fraction, did not change significantly from baseline at any time-point. During a median follow-up of 44 months (range, 2-73), seven patients (9%), all of whom had received prior imatinib therapy, developed 11 clinical cardiac adverse events requiring treatment. The median time from the start of nilotinib therapy to an event was 14.5 months (range, 2-68). Five of seven patients were able to continue nilotinib therapy with only one brief interruption. ConclusionsWhereas new electrocardiographic abnormalities were recorded in 20% of all patients and some of them developed severe or even life-threatening coronary artery disease, QT prolongation, changes in left ventricular ejection fraction, and clinical cardiac adverse events were uncommon in patients treated with nilotinib.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical cardiac safety profile of nilotinib

Kim¹,

Coutre²,

Schwarz³

et al. 2012

Haematologica

View full text Add to dashboard Cite

show abstract

“…Imb-induced inhibition of C-Ab1 might contribute to endogenous antioxidant depletion thus, C-Ab1 might be important in the control of cellular antioxidant defense mechanisms. Imb mesylate-induced cardiac toxicity is also facilitated by several relevant co-morbidities such as previous cardiovascular disease or renal failure [51].…”

Section: Discussionmentioning

confidence: 99%

Study of Imatinib Cardiotoxicity In Adult Male Rabbits

Hassan¹,

Yousef²

2013

IOSR-JESTFT

View full text Add to dashboard Cite

show abstract

“…49 Although imatinib-induced LV dysfunction is largely reversible after discontinuing the treatment, persistent and irreversible heart failure has also been reported. 50 Other than LV dysfunction, imatinib typically induces periorbital or peripheral edema through a non-cardiogenic mechanism with an unknown etiology.…”

Section: Other Biological Agentsmentioning

confidence: 99%